{"id":"rhg-csf-rhgm-csf-group","safety":{"commonSideEffects":[{"rate":null,"effect":"Bone pain"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Splenomegaly"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"rhG-CSF and rhGM-CSF are cytokines that bind to their respective receptors on hematopoietic progenitor cells, promoting differentiation and proliferation of granulocytes and macrophages. The combination approach leverages complementary signaling pathways to achieve enhanced mobilization of bone marrow-derived cells and improved immune cell function, particularly useful in settings of chemotherapy-induced neutropenia or hematopoietic stem cell transplantation.","oneSentence":"This combination of recombinant human granulocyte colony-stimulating factor (rhG-CSF) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) stimulates the production and activation of neutrophils and myeloid cells to enhance immune function and hematopoietic recovery.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:05:01.888Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chemotherapy-induced neutropenia"},{"name":"Hematopoietic stem cell transplantation support"},{"name":"Bone marrow recovery enhancement"}]},"trialDetails":[{"nctId":"NCT01232504","phase":"PHASE4","title":"Antifugal Effect of Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) in Patients Post Allo-HSCT","status":"COMPLETED","sponsor":"Xiamen Amoytop Biotech Co., Ltd.","startDate":"2009-09","conditions":"Mycoses","enrollment":206}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Topleucon®","Granulocyte Macrophage Colony Stimulating Factor","Granulocyte Colony Stimulating Factor"],"phase":"marketed","status":"active","brandName":"rhG-CSF+rhGM-CSF group","genericName":"rhG-CSF+rhGM-CSF group","companyName":"Xiamen Amoytop Biotech Co., Ltd.","companyId":"xiamen-amoytop-biotech-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination of recombinant human granulocyte colony-stimulating factor (rhG-CSF) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) stimulates the production and activation of neutrophils and myeloid cells to enhance immune function and hematopoietic recovery. Used for Chemotherapy-induced neutropenia, Hematopoietic stem cell transplantation support, Bone marrow recovery enhancement.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}